

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ACTIMMUNE

---

### Products Affected

- ACTIMMUNE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	None
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ADEMPAS

---

### Products Affected

- ADEMPAS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of pulmonary arterial hypertension (WHO group I) AND diagnosis was confirmed by right heart catheterization OR Patient has a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH, WHO group 4) AND patient has persistent or recurrent disease after surgical treatment (e.g., pulmonary endarterectomy) or has CTEPH that is inoperable AND female patients are enrolled in the ADEMPAS REMS program.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or cardiologist.
<b>Coverage Duration</b>	6 months - initial. 12 months - renewal
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ALECENSA

---

### Products Affected

- ALECENSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of metastatic anaplastic lymphoma kinase positive non-small cell lung cancer.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ALPHA1-PROTEINASE INHIBITOR

---

### Products Affected

- PROLASTIN-C INTRAVENOUS  
SOLUTION RECONSTITUTED 1000  
MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Patient has IgA deficiency with antibodies against IgA.
<b>Required Medical Information</b>	Alpha1-proteinase inhibitor concentration is less than 11 micromoles per liter. The FEV1 level is between 35% and 60% predicted OR greater than 60% predicted. If the FEV1 is greater than 60% predicted, then the patient has experienced a rapid decline in lung function (ie, reduction of FEV1 more than 120 mL/year) that warrants treatment.
<b>Age Restrictions</b>	18 years old and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ALUNBRIG

---

### Products Affected

- ALUNBRIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of metastatic, ALK positive non-small cell lung cancer and have progressed or are intolerant to Xalkori (crizotinib)
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a oncologist
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## AMPHETAMINES

### Products Affected

- *amphetamine-dextroamphet er*
- *dextroamphetamine sulfate er*
- *dextroamphetamine sulfate oral tablet*
- VYVANSE

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	MAOI concurrent use or within the last 14 days except if prescriber is a psychiatrist with experience prescribing both MAOI and amphetamine/dextroamphetamine drugs.
Required Medical Information	Sleep studies for narcolepsy diagnosis
Age Restrictions	3 years of age and older for amphetamine ER and Dextroamphetamine IR, 6 years of age and older for Vyvanse and Dextroamphetamine ER
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Consider benefits of use versus the potential risks of serious cardiovascular events

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ARCALYST

---

### Products Affected

- ARCALYST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Active or chronic infection. Concurrent therapy with other biologics.
<b>Required Medical Information</b>	None
<b>Age Restrictions</b>	12 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	For renewal, patient's condition must have improved or stabilized.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ARIKAYCE

---

### Products Affected

- ARIKAYCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of Pulmonary Mycobacterium avium complex infection and used as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with infectious disease specialist or pulmonologist
<b>Coverage Duration</b>	Initial: 6 months, Renewal: 12 months
<b>Other Criteria</b>	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ARMODAFINIL

---

### Products Affected

- *armodafinil*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of Shift Work Sleep Disorder frequently (5 times or more per month) AND experience excessive sleepiness while working or diagnosis of mild obstructive sleep apnea/hypopnea syndrome.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## AUBAGIO

---

### Products Affected

- AUBAGIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Severe hepatic impairment. Current treatment with leflunomide. Patients who are pregnant or women of childbearing potential not using reliable contraception.
<b>Required Medical Information</b>	Diagnosis of relapsing forms of multiple sclerosis (e.g., relapsing-remitting MS or progressive-relapsing MS) OR patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	For renewal, patient has experienced an objective response to therapy (i.e., no or slowed progression of disease)

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## AURYXIA

---

### Products Affected

- AURYXIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	For the management of hyperphosphatemia in patients with chronic kidney disease on dialysis
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## AUSTEDO

### Products Affected

- AUSTEDO

PA Criteria	Criteria Details
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Any degree of hepatic impairment or hepatic disease, Patients with active suicidal ideation or who have untreated or inadequately treated depression
<b>Required Medical Information</b>	A. CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE: Diagnosis of Chorea associated with Huntington's disease AND prescriber attestation that patient has NOT taken an MAOI in the past 14 days OR B. TARDIVE DYSKINESIA: Diagnosis of medication induced tardive Dyskinesia AND patient has a history of using a dopamine receptor antagonist
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a psychiatrist or neurologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## BOSULIF

### Products Affected

- BOSULIF

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of Philadelphia chromosome-positive (Ph+) CML with resistance, relapse, or inadequate response to prior therapy with one of the following tyrosine kinase inhibitors (TKI): Gleevec [imatinib], Tassigna [nilotinib], Sprycel [dasatinib] OR newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph + CML)
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## BRAFTOVI

---

### Products Affected

- BRAFTOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of unresectable or metastatic malignant melanoma with documented BRAF V600E or V600K mutation as detected by an FDA-approved test used in combination with binimetinib
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a oncologist
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## CABOMETYX

---

### Products Affected

- CABOMETYX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of advanced or metastatic renal cell cancer (RCC).
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## CALQUENCE

---

### Products Affected

- CALQUENCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	MANTLE CELL LYMPHOMA (MCL) (1) Patient must have a diagnosis of MCL AND (2) Patient has tried one other therapy
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## CAYSTON

### Products Affected

- CAYSTON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of cystic fibrosis is confirmed by appropriate diagnostic or genetic testing. Confirmation of <i>P. aeruginosa</i> in cultures of the airways. For continuation of therapy, a clinical reason to continue therapy, such as symptomatic improvement or pulmonary function tests have not deteriorated more than 10% from baseline.
<b>Age Restrictions</b>	7 years of age or older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	For renewal, Patient is benefiting from treatment (i.e., improvement in lung function [FEV1], decreased number of pulmonary exacerbations)

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## COPIKTRA

---

### Products Affected

- COPIKTRA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of relapsed or refractory: A) chronic lymphocytic leukemia OR B) small lymphocytic lymphoma OR C) Follicular lymphoma. Used in patients with history of 2 prior therapies
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or hematologist
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## CORLANOR

### Products Affected

- CORLANOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Decompensated acute heart failure, hypotension (i.e. blood pressure less than 90/50 mmHg), sick sinus syndrome or sinoatrial block or 3rd degree AV block (unless a functioning demand pacemaker is present), or bradycardia (i.e., resting heart rate less than 60 bpm prior to treatment).
<b>Required Medical Information</b>	Patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction 35% or less, who are in sinus rhythm with resting heart rate 70 beats per minute or more and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## COTELLIC

---

### Products Affected

- COTELLIC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of unresectable OR metastatic malignant melanoma with BRAF V600E OR V600K mutation AND documentation of combination therapy with vemurafenib.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	Cotellic is not indicated for the treatment of patients with wild-type BRAF melanoma

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## CYSTARAN

---

### Products Affected

- CYSTARAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Patient has a diagnosis of cystinosis AND Patient has corneal cystine crystal accumulation
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## DALFAMPRIDINE

---

### Products Affected

- *dalfampridine er*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	History of seizure. Moderate or severe renal impairment (creatinine clearance less than or equal to 50 mL/minute).
<b>Required Medical Information</b>	Diagnosis of multiple sclerosis. Patient must demonstrate sustained walking impairment, but with the ability to walk 25 feet (with or without assistance) prior to starting Ampyra.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Initial - 3 months. Renewal - 12 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## DICLOFENAC TOPICAL

---

### Products Affected

- *diclofenac sodium transdermal gel 3 %*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diclofenac 3% gel: Diagnosis of actinic keratosis
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## DRONABINOL

### Products Affected

- dronabinol*

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	A. The diagnosis is documented as anorexia associated with weight loss in a patient with AIDS a. AND the patient has had an involuntary weight loss of greater than 10% of pre-illness baseline body weight or a body mass index (BMI) less than 20kg/m <sup>2</sup> in the absence of a concurrent illness or medical condition other than HIV that may cause weight loss b. AND the patient has failed to respond to a 30-day drug regimen of megestrol (Megace) c. AND if the patient has received previous dronabinol therapy, he/she must show a positive response to therapy by maintaining or increasing their initial weight and/or muscle mass before initiating dronabinol therapy. B. The diagnosis is documented as nausea and vomiting associated with cancer chemotherapy in a cancer patient a. AND the patient is receiving a chemotherapy or radiation regimen b. AND the patient has had a full trial and failure through at least one cycle of chemotherapy with IV ondansetron AND at least one of the following oral anti-emetic agents: metoclopramide, promethazine, prochlorperazine, meclizine, trimethobenzamide, oral 5-HT <sub>3</sub> receptor antagonists e. AND if the patient has received previous dronabinol therapy, he/she must show a positive response by showing a reduced incidence of emesis and/or nausea.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	B vs D coverage determination per CMS guidelines

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ENBREL

### Products Affected

- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Active serious infection (including tuberculosis). Combined use with a biologic disease-modifying anti-rheumatic drugs or potent immunosuppressant (e.g., azathioprine or cyclosporine)
<b>Required Medical Information</b>	Diagnosis of moderate to severe rheumatoid arthritis and patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs for at least 3 consecutive months OR Diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis and patient had an inadequate response, intolerance or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs) for at least 3 consecutive months OR Diagnosis of psoriatic arthritis and patient had an inadequate response, intolerance, or contraindication to methotrexate OR Diagnosis of ankylosing spondylitis and patient had an inadequate response, intolerance or contraindication to one or more NSAIDs OR Diagnosis of moderate to severe chronic plaque psoriasis (affecting more than 5% of body surface area or affecting crucial body areas such as the hands, feet, face, or genitals) and patient had an inadequate response, intolerance or contraindication to conventional therapy with at least one of the following: phototherapy (including but not limited to Ultraviolet A with a psoralen [PUVA] and/or retinoids [RePUVA] for at least one continuous month or one or more oral systemic treatments (i.e. methotrexate, cyclosporine, acitretin, sulfasalazine) for at least 3 consecutive months.
<b>Age Restrictions</b>	2 years of age or older for JIA or JRA. 4 years of age or older for plaque psoriasis. 18 years of age or older for all other indications
<b>Prescriber Restrictions</b>	None

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019

# CARE N' CARE HEALTH PLAN

## 2019 Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ENDARI

---

### Products Affected

- ENDARI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of acute sickle cell disease AND patient must have trial history of Hydroxyurea. Otherwise Endari requires documentation of (1) history of inadequate treatment with Hydroxyurea OR (2) history of adverse event with Hydroxyurea OR (3) Hydroxyurea is contraindicated.
<b>Age Restrictions</b>	5 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ENTRESTO

---

### Products Affected

- ENTRESTO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	History of angioedema related to previous ACE inhibitor or ARB therapy, concomitant use or use within 36 hours of ACE inhibitors, concomitant use of aliskiren in patients with diabetes
<b>Required Medical Information</b>	Statement of diagnosis indicating Heart Failure (NYHA Class II through IV).
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## EPIDIOLEX

---

### Products Affected

- EPIDIOLEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of Lennox-Gastaut syndrome OR severe myoclonic epilepsy in infancy
<b>Age Restrictions</b>	2 years of age and older
<b>Prescriber Restrictions</b>	Prescriber by or consultation with a neurologist
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ERLEADA

---

### Products Affected

- ERLEADA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Pregnancy
<b>Required Medical Information</b>	Diagnosis of nonmetastatic, castration-resistant prostate cancer.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or urologist
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ESBRIET

---

### Products Affected

- ESBRIET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Appropriate diagnosis (idiopathic pulmonary fibrosis [IPF]) and monitoring (hepatic function/LFTs)
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ESRD THERAPY

---

### Products Affected

- PROCRT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Pretreatment hemoglobin levels of less than 10g/dL. Dose reduction or interruption if hemoglobin exceeds 10 g/dL (CKD not on dialysis-adult, cancer), 11 g/dL (CKD on dialysis), 12 g/dL (pediatric CKD) in addition to supporting statement of diagnosis from physician.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## EXJADE

---

### Products Affected

- EXJADE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Medical documentation of FDA approved diagnosis, serum ferritin levels, and serum creatinine.
<b>Age Restrictions</b>	Covered for those 2 years of age and older with chronic iron overload due to blood transfusions
<b>Prescriber Restrictions</b>	Hematologist
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## FARYDAK

---

### Products Affected

- FARYDAK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of Multiple Myeloma (MM) Used in combination with both of the following: Velcade (bortezomib) and dexamethasone. Patient has received at least two prior treatment regimens which included both of the following: Velcade (bortezomib) and an immunomodulatory agent [e.g., Revlimid (lenalidomide), Thalomid (thalidomide)].
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist/hematologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## FENTANYL ORAL

---

### Products Affected

- *fentanyl citrate buccal*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Patients taking strong or moderate cytochrome P450 3A4 inhibitor(s) (e.g., aprepitant, clarithromycin, diltiazem, erythromycin, fosamprenavir, fluconazole, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, verapamil) who will not be monitored or have dosing adjustments made if necessary.
<b>Required Medical Information</b>	None
<b>Age Restrictions</b>	16 years of age and older (fentanyl oral lozenge)
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## FORTEO

### Products Affected

- FORTEO SUBCUTANEOUS SOLUTION 600 MCG/2.4ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Patient meets one of the following criteria: 1) Patient has experienced a prior fragility fracture, or 2) Patient had an inadequate response to an adequate trial of a bisphosphonate (one year) or patient has a contraindication or intolerance to bisphosphonate trial, or 3) Patient has 2 of the following risk factors for fracture: advanced age, parental history of fracture, low body mass index, current smoker, chronic alcohol use, rheumatoid arthritis, chronic steroid use, or other secondary cause of osteoporosis.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## GALAFOLD

---

### Products Affected

- GALAFOLD

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of Fabry disease with an amenable galactosidase alpha gene (GLA) mutation
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## GILENYA

### Products Affected

- GILENYA ORAL CAPSULE 0.5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Recent (within the last 6 months) occurrence of: myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure. History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker. Baseline QTc interval greater than or equal to 500 ms. Receiving concurrent treatment with Class Ia or Class III anti-arrhythmic drugs (quinidine, procainamide, amiodarone, sotalol).
<b>Required Medical Information</b>	Diagnosis of a relapsing form of multiple sclerosis or diagnosis of first clinical episode with MRI features consistent with MS AND Patient will be observed for signs and symptoms of bradycardia in a controlled setting for at least 6 hours after the first dose
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Initial - 6 months. Renewal - 12 months
<b>Other Criteria</b>	For renewal, the patient has experienced no or slowed disease progression.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## GILOTRIF

### Products Affected

- GILOTRIF

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Supporting statement of diagnosis from the physician in patients with: 1) metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test or 2) metastatic squamous NSCLC, progressing after platinum-based chemotherapy.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## GLATIRAMER

---

### Products Affected

- *glatiramer acetate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of relapsing-remitting multiple sclerosis OR diagnosis of first clinical episode with MRI features consistent with multiple sclerosis
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	For renewal, patient has no or slowed disease progression



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## GOCOVRI

### Products Affected

- GOCOVRI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Patients with ESRD (CrCl below 15 ml/min/m <sup>2</sup> )
<b>Required Medical Information</b>	INITIAL: Diagnosis of Parkinsons disease AND (1) Patient is experiencing dyskinesia AND (2) Patient is receiving levodopa based therapy AND (3) Must have documented trial and failure to amantadine immediate release. RENEWAL: (1) must meet the initial criteria above AND (2) Documentation of positive clinical response to Gocovri (e.g., decreased off periods, decreased on time with troublesome dyskinesia)
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## GROWTH HORMONE

### Products Affected

- NORDITROPIN FLEXPRO

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For pediatric GHD in neonate with hypoglycemia: patient has a randomly assessed GH level less than 20 ng/mL, other causes of hypoglycemia have been ruled out, and other treatments have been ineffective. For all pediatric patients: patients have short stature or slow growth velocity and have been evaluated for other causes of growth failure. For pediatric GHD, patient has delayed bone age. For pediatric GHD without pituitary disease, patient failed 2 stimulation tests. For pediatric GHD with a pituitary or CNS disorder, patient has clinical evidence of GHD and low IGF-1/IGFBP3. For TS and SHOX patients: diagnosis confirmed by genetic testing. For CRI patients: metabolic, endocrine and nutritional abnormalities have been treated or stabilized and patient has not had a kidney transplant. For SGA: patient has a low birth weight or length for gestational age. For ISS: pediatric GHD has been ruled out with one stimulation test. For adult GHD, patient was assessed for other causes of GHD-like symptoms. For adult GHD without pituitary disease, patient failed 2 stimulation tests. For adult GHD with at least 3 pituitary hormone deficiencies (PHD) or panhypopituitarism: have a low IGF-1. For adult GHD with less than 3 PHD, low IGF-1 and failed one stimulation test. For renewal for adult patients: patient has seen clinical improvement and IGF-1 will be monitored.
Age Restrictions	For Turner syndrome and SGA, 2 years of age and older. For Noonan syndrome and SHOX, 3 years of age and older.
Prescriber Restrictions	Endocrinologist, Pediatric Nephrologist, Gastroenterologist, Nutritional Support Specialist, Infectious Disease Specialist
Coverage Duration	Plan Year
Other Criteria	None

Formulary ID 19516, Ver 7

Last Updated 1/23/2019

Effective 2/1/2019

**CARE N' CARE HEALTH PLAN**  
2019 Prior Authorization Criteria

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HEPATITIS C

### Products Affected

- MAVYRET
- VOSEVI

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Must submit documentation of chronic hepatitis C genotype (confirmed by HCV RNA level within the last 6 months). Must submit laboratory results within 12 weeks of initiating therapy including: 1) CBC w Platelets, 2) AST/ALT, 3)Total Bilirubin, 4)Serum Albumin, 5)PT/INR, 6)Serum Creatinine, and 7)GFR. FOR ALL GENOTYPES: Trial/failure, contraindication to, or intolerance to Mavyret is required prior to approval of Vosevi.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescriber must be a gastroenterologist, hepatologist, or infectious disease specialist
Coverage Duration	Duration of approval per AASLD Guidelines
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HETLIOZ

---

### Products Affected

- HETLIOZ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of Non-24-hour-sleep-wake disorder (Non-24) AND patient has documented blindness
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	6 months (initial), 12 months (renewal)
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ADHD

---

### Products Affected

- *guanfacine hcl oral*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
<b>Age Restrictions</b>	For patients less than or equal to 64 years, claim will automatically pay.
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ANALGESICS

### Products Affected

- ASCOMP-CODEINE
- *butalbital-apap-caff-cod oral capsule 50-325-40-30 mg*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*
- *indomethacin er*
- *indomethacin oral*

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
Age Restrictions	For patients less than or equal to 64 years, claim will automatically pay.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ANTI-ARRHYTHMICS

---

### Products Affected

- *disopyramide phosphate oral*
- NORPACE CR

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D. Disopyramide: rate control preferred for atrial fibrillation
Age Restrictions	For patients less than or equal to 64 years, claim will automatically pay.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ANTIDEPRESSANTS

---

### Products Affected

- *amitriptyline hcl oral*
- *clomipramine hcl oral*
- *doxepin hcl oral*
- *imipramine hcl oral*
- *imipramine pamoate*
- *trimipramine maleate oral*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
<b>Age Restrictions</b>	For patients less than or equal to 64 years, claim will automatically pay.
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ANTIEMETIC DRUGS

### Products Affected

- *hydroxyzine hcl oral syrup*
- *hydroxyzine hcl oral tablet*
- *hydroxyzine pamoate oral*
- *promethazine hcl oral syrup*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal*
- *trimethobenzamide hcl oral*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D. Formulary non HRM alternatives are as follows Nausea/Vomiting: granisetron, ondansetron_Allergic Reactions: levocetirizine
<b>Age Restrictions</b>	For patients less than or equal to 64 years, claim will automatically pay.
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ANTIHISTAMINES

---

### Products Affected

- *carbinoxamine maleate oral solution*
- *carbinoxamine maleate oral tablet 4 mg*
- *clemastine fumarate oral tablet 2.68 mg*
- *cyproheptadine hcl oral*
- *promethazine vc plain oral solution*
- *promethazine-phenylephrine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
<b>Age Restrictions</b>	For patients less than or equal to 64 years, claim will automatically pay.
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ANTIPARKINSON AGENTS

---

### Products Affected

- *benztropine mesylate oral*
- *trihexyphenidyl hcl*

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
Age Restrictions	For patients less than or equal to 64 years, claim will automatically pay.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ANTIPSYCHOTICS

---

### Products Affected

- *perphenazine-amitriptyline*
- *thioridazine hcl oral*

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
Age Restrictions	For patients less than or equal to 64 years, claim will automatically pay.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - BARBITURATES

---

### Products Affected

- *phenobarbital oral elixir*
- *phenobarbital oral tablet*

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D. Formulary non HRM alternatives are as follows a) ANXIETY: (citalopram, escitalopram, fluvoxamine, sertraline, duloxetine, venlafaxine, buspirone). b) INSOMNIA: low dose trazodone)
Age Restrictions	For patients less than or equal to 64 years, claim will automatically pay.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - DEMENTIA AGENTS

---

### Products Affected

- *ergoloid mesylates oral*

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D. Formulary non HRM alternatives are as follows Antidementia: donepezil,galantamine, memantine ER,rivastigmine capsule, rivastigmine patch.
Age Restrictions	For patients less than or equal to 64 years, claim will automatically pay.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ONCOLOGY

### Products Affected

- *megestrol acetate oral suspension 40 mg/ml, 625 mg/5ml*
- *megestrol acetate oral tablet*

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D. Formulary non HRM alternatives for diagnosis of cachexia secondary to chronic illness (dronabinol, oxandrolone)
Age Restrictions	For patients less than or equal to 64 years, claim will automatically pay.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - ORAL AND TRANSDERMAL ESTROGENS AND PROGESTINS

### Products Affected

- CLIMARA PRO
- COMBIPATCH
- DIVIGEL TRANSDERMAL GEL 1 MG/GM
- DUAVEE
- *estradiol oral*
- *estradiol transdermal*
- *estradiol-norethindrone acet*
- *estropipate oral tablet 0.75 mg*
- EVAMIST
- FYAVOLV
- JINTELI
- MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG
- *norethindrone-eth estradiol*
- PREFEST
- PREMARIN ORAL
- PREMPHASE
- PREMPRO

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D. Formulary non HRM alternatives are as follows Localized options: Premarin Cream and Estradiol Cream. Osteoporosis: Alendronate and Risedronate.
Age Restrictions	For patients less than or equal to 64 years, claim will automatically pay.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - PLATELET INHIBITORS

---

### Products Affected

- *dipyridamole oral*

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D. Formulary non HRM alternatives are as follows Platelet Inhibitors: Cilostazol, Clopidogrel.
Age Restrictions	For patients less than or equal to 64 years, claim will automatically pay.
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - SEDATIVE HYPNOTIC AGENTS

---

### Products Affected

- *eszopiclone*
- *zaleplon*
- *zolpidem tartrate er*
- *zolpidem tartrate oral*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
<b>Age Restrictions</b>	For patients less than or equal to 64 years, claim will automatically pay.
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HRM - SKELETAL MUSCLE RELAXANTS

### Products Affected

- *chlorzoxazone oral tablet 500 mg*
- *cyclobenzaprine hcl oral*
- *metaxalone oral tablet 800 mg*
- *methocarbamol oral*
- *orphenadrine citrate er*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D.
<b>Age Restrictions</b>	For patients less than or equal to 64 years, claim will automatically pay.
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## HUMIRA

### Products Affected

- HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT
- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT
- HUMIRA PEN-CD/UC/HS STARTER
- HUMIRA PEN-PS/UV/ADOL HS START
- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Active serious infection (including tuberculosis). Combined use with a biologic disease-modifying anti-rheumatic drugs or potent immunosuppressant (e.g., azathioprine or cyclosporine)
Required Medical Information	Diagnosis of ONE of the following: A) moderate to severe rheumatoid arthritis OR moderate to severe polyarticular juvenile idiopathic arthritis and patient had inadequate response, intolerance, or contraindication to one or more non-biologic DMARDs for at least 3 consecutive months B) psoriatic arthritis and patient had inadequate response, intolerance, or contraindication to methotrexate C) ankylosing spondylitis and patient had inadequate response, intolerance, or contraindication to one or more NSAIDs D) moderate to severe chronic plaque psoriasis (affecting more than 5% of body surface area or affecting crucial body areas such as the hands, feet, face, or genitals) and patient had inadequate response, intolerance, or contraindication to conventional therapy with at least one of the following: phototherapy (including but not limited to UVA with a psoralen [PUVA] and/or retinoids [RePUVA] for at least one continuous month or one or more oral systemic treatments (Cyclosporine, acitretin, sulfasalazine, methotrexate, leflunomide, azathioprine) for at least 3 consecutive months E) moderate to severe Crohn's disease and patient had inadequate response, intolerance, or contraindication to conventional therapy with two or more of the following: corticosteroids or non-biologic DMARDs F) moderate to severe ulcerative colitis and patient had inadequate response, intolerance or contraindication to conventional therapy with two or more of the following: corticosteroids, 5-ASA (i.e. mesalamine, sulfasalazine, balsalazide) or non-biologic DMARDs (azathioprine, cyclosporine, hydroxychloroquine, leflunomide, sulfasalazine) G) non-infectious uveitis (including intermediate, posterior, and panuveitis) and patient had inadequate response, intolerance or

Formulary ID 19516, Ver 7  
 Last Updated 1/23/2019  
 Effective 2/1/2019

# CARE N' CARE HEALTH PLAN

## 2019 Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
	contraindication to conventional therapy with one of the following: systemic or topical corticosteroids or ophthalmic antimuscarinics. OR H) moderate to severe hidradenitis suppurativa
<b>Age Restrictions</b>	2 years of age or older for JIA or uveitis. 6 years of age or older for pediatric Crohn's disease, 12 years of age or older for hidradenitis suppurativa, 18 years of age or older for all other indications
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## IBRANCE

### Products Affected

- IBRANCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy OR in combination with fulvestrant in women with disease progression following endocrine therapy.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ICLUSIG

### Products Affected

- ICLUSIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) in adult patients who are T315I-positive or for whom no other tyrosine kinase inhibitor therapy is indicated OR Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adult patients who are T315I-positive or for whom no other tyrosine kinase inhibitor therapy is indicated
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or hematologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## IDHIFA

---

### Products Affected

- IDHIFA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation as detected by an FDA approved test
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or hematologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## IMBRUVICA

---

### Products Affected

- IMBRUVICA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Supporting statement of diagnosis from the physician
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## INCRELEX

### Products Affected

- INCRELEX

PA Criteria	Criteria Details
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Increlex is contraindicated in patients with allergies to mecasermin or any component of the Increlex formulation, for growth promotion in patients with closed epiphyses, for IV administration, in patients with active or suspected neoplasia. Increlex should be discontinued if neoplasia develops while on therapy.
<b>Required Medical Information</b>	Increlex (mecasermin [rDNA origin] injection) is indicated for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Child has one of the following conditions: Severe primary IGF-1 deficiency, OR Growth hormone gene deletion with developed neutralizing antibodies to growth hormone, OR Genetic mutation of GH receptor (i.e. Laron Syndrome), AND Child has severe growth retardation with height standard deviation score (SDS) more than 3 SDS below the mean for chronological age and sex, AND Child with IGF-1 level greater than or equal to 3 standard deviations below normal based on lab reference range for age and sex, AND Child with normal or elevated growth hormone (GH) levels based on at least one growth hormone stimulation test, AND Evidence of open epiphyses
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Pediatric or Endocrinologist
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	None

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## INTRAROSA

---

### Products Affected

- INTRAROSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Vaginal bleeding or dysfunctional uterine bleeding of an undetermined origin, known or suspected estrogen-dependent neoplasia.
<b>Required Medical Information</b>	Diagnosis of moderate to severe dyspareunia or atrophic vaginitis due to menopause.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## IRESSA

### Products Affected

- IRESSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Non-small cell lung cancer (NSCLC): Diagnosis of metastatic NSCLC AND Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ITRACONAZOLE

### Products Affected

- *itraconazole oral capsule*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	A. ventricular dysfunction (e.g., congestive heart failure (CHF) or history of CHF) do not use for onychomycosis. B. If the patient is taking/receiving any of the following: concomitant use with drugs metabolized by CYP3A4 (e.g., cisapride, dofetilide, pimozide, quinidine)
<b>Required Medical Information</b>	Patients with a diagnosis of blastomycosis, pulmonary or extrapulmonary OR patients with a diagnosis of histoplasmosis, including chronic cavitary pulmonary disease or disseminated, non-meningeal histoplasmosis OR patients with a diagnosis of aspergillosis, pulmonary or extrapulmonary OR patients with a diagnosis of onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium) OR patients with a diagnosis of onychomycosis of the fingernail due to dermatophytes (tinea unguium). For onychomycosis, diagnosis has been confirmed with a fungal diagnostic test (e.g., KOH preparation, fungal culture, or nail biopsy).
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	12 weeks
<b>Other Criteria</b>	None

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## IVIG

### Products Affected

- BIVIGAM INTRAVENOUS SOLUTION 10 GM/100ML
- CARIMUNE NF INTRAVENOUS SOLUTION RECONSTITUTED 6 GM
- FLEBOGAMMA DIF INTRAVENOUS SOLUTION 5 GM/50ML
- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	IgA deficiency with antibody formation and a history of hypersensitivity. History of anaphylaxis or severe systemic reaction to human immune globulin. Presence of risk factor(s) for acute renal failure, unless the patient will receive IGIV products at the minimum concentration available and at the minimum rate of infusion practicable.
Required Medical Information	None
Age Restrictions	None
Prescriber Restrictions	CIDP diagnosis by a neurologist
Coverage Duration	Plan Year
Other Criteria	Gamunex/Gamunex-C: if administered SC outside of a controlled healthcare setting, appropriate treatment (eg, anaphylaxis kit) should be available for managing an acute hypersensitivity reaction.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## JUXTAPID

### Products Affected

- JUXTAPID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Moderate to severe liver impairment or active liver disease including unexplained persistent abnormal liver function tests. Pregnancy. Concomitant use with strong or moderate CYP3A4 inhibitors.
<b>Required Medical Information</b>	Diagnosis of homozygous familial hypercholesterolemia AND Patient has tried and had an inadequate response or intolerance to statins
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## KALYDECO

### Products Affected

- KALYDECO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Cystic Fibrosis (Initial): Diagnosis of cystic fibrosis AND the patient has 1 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data. (Reauthorization): Documentation of one of the following while on Kalydeco therapy: Improved lung function or stable lung function.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## KISQALI

### Products Affected

- KISQALI 200 DOSE
- KISQALI 400 DOSE
- KISQALI 600 DOSE
- KISQALI FEMARA 200 DOSE
- KISQALI FEMARA 400 DOSE
- KISQALI FEMARA 600 DOSE

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	KISQALI: Breast Cancer: A) Metastatic or advanced, HER-2 negative, hormone receptor-positive, postmenopausal women in combination with fulvestrant as initial endocrine based therapy or following disease progression on endocrine therapy, B) Metastatic or advanced, HER-2 negative, hormone receptor-positive, premenopausal, perimenopausal or postmenopausal women, in combination with an aromatase inhibitor for initial endocrine-based treatment. KISQALI FEMARA: HER-2 negative, hormone receptor-positive, advanced or metastatic breast cancer in postmenopausal women.
Age Restrictions	Age 18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a oncologist
Coverage Duration	Plan year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## KORLYM

---

### Products Affected

- KORLYM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Pregnancy
<b>Required Medical Information</b>	Supporting statement of diagnosis from the physician
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## KUVAN

### Products Affected

- KUVAN

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Blood phenylalanine (Phe) levels. Pretreatment blood phenylalanine (Phe) levels greater than 10mg/dL if the patient is older than 12 years of age or greater than 6mg/dL if less than or equal to 12 years of age. Response to a therapeutic trial (greater than or equal to a 30% reduction in blood Phe levels) is required for long-term authorization.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Initial: 2 months. Renewal: 12 months.
Other Criteria	Blood Phe levels should be checked after 1 week of therapy and periodically up to one month during a therapeutic trial.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## KYNAMRO

### Products Affected

- KYNAMRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Moderate to severe liver impairment or active liver disease including unexplained persistent abnormal liver function tests.
<b>Required Medical Information</b>	Diagnosis of homozygous familial hypercholesterolemia AND Patient has tried and had an inadequate response or intolerance to statins
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Initial - 6 months. Renewal - 12 months
<b>Other Criteria</b>	For renewal, patient has responded to therapy with a decrease in LDL levels.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## LENVIMA

---

### Products Affected

- LENVIMA 10 MG DAILY DOSE
- LENVIMA 12 MG DAILY DOSE
- LENVIMA 14 MG DAILY DOSE
- LENVIMA 18 MG DAILY DOSE
- LENVIMA 20 MG DAILY DOSE
- LENVIMA 24 MG DAILY DOSE
- LENVIMA 4 MG DAILY DOSE
- LENVIMA 8 MG DAILY DOSE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer OR advanced renal cell carcinoma following one prior anti-angiogenic therapy in combination with everolimus
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## LETAIRIS

### Products Affected

- LETAIRIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Pregnancy
<b>Required Medical Information</b>	Diagnosis of pulmonary arterial hypertension that was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.) AND Patient has WHO Group I PAH AND pregnancy must be excluded prior to the start of therapy. Female patients of childbearing age will be educated about the potential hazards associated with Letairis use in pregnancy.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or cardiologist.
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	IUD (intrauterine device) or two appropriate contraceptive methods will be used for women of childbearing potential.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## LEUKINE

### Products Affected

- LEUKINE INTRAVENOUS

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Administration within 24 hours preceding or following chemotherapy or radiotherapy, hypersensitivity to yeast-derived products. For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule above established regimens. For treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle. For AML only, excessive (greater than or equal to 10%) leukemic myeloid blasts in the bone marrow or peripheral blood.
<b>Required Medical Information</b>	For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy: Leukine may be used for the prevention of chemotherapy-induced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia. Patients at low risk (less than 10%) for developing febrile neutropenia may also receive Leukine for prophylaxis if there is a significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease. Leukine is allowable for the treatment of febrile neutropenia in patients who have received prophylaxis with Leukine (or Neupogen) OR in patients at risk for infection-related complications. All patients must receive baseline and regular monitoring of complete blood counts and platelet counts.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	None

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## LIDOCAINE PATCH

### Products Affected

- *lidocaine external patch 5 %*
- ZTLIDO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Supporting statement of diagnosis from the physician
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	For the FDA-labeled indication of post-herpetic neuralgia, no additional criteria are required to be met. For diabetic neuropathy: the patient must have previous use and inadequate response or intolerance to any ONE neuropathic pain medication, including (but not limited to) Cymbalta and Lyrica that are labeled for neuropathic pain.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## LORBRENA

### Products Affected

- LORBRENA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	Concomitant use with strong CYP3A4 inducers
Required Medical Information	Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with disease progression on alectinib as the first ALK inhibitor therapy for metastatic disease, OR ceritinib as first ALK inhibitor therapy for metastatic disease, OR crizotinib and at least one other ALK inhibitor for metastatic disease.
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a oncologist
Coverage Duration	Plan year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## LUPRON

### Products Affected

- *leuprolide acetate injection*
- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Pregnancy in patients with child-bearing potential. Breastfeeding. Undiagnosed abnormal vaginal bleeding.
Required Medical Information	Diagnosis of one of the following: A) Advanced or metastatic prostate cancer (7.5 mg 1-month, 22.5 mg 3-month, 30 mg 4-month, & 45 mg 6-month depots only), B) Endometriosis (3.75 mg 1-month & 11.25 mg 3-month depots only), C) Anemia due to uterine Leiomyomata (Fibroids) (3.75 mg 1-month & 11.25 mg 3-month depots only) and Patient is preoperative, D) Central precocious puberty (idiopathic or neurogenic) in children
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Endometriosis- 6 months, Uterine fibroids -3 months, Prostate cancer, Precocious Puberty -12 months
Other Criteria	For endometriosis and uterine fibroids, patient will be using nonhormonal contraception during and for 12 weeks after therapy.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## LYNPARZA

### Products Affected

- LYNPARZA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Supporting statement with diagnosis of 1) deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer and have been treated with 3 or more prior lines of chemotherapy OR 2) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and have a complete or partial response to platinum-based chemotherapy OR 3) HER2-negative, deleterious or suspected deleterious germline BRCA mutated (gBRCAm) metastatic breast cancer and have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## MEKINIST

---

### Products Affected

- MEKINIST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of unresectable or metastatic melanoma with documented BRAF V600E or V600K mutations as detected by an FDA-approved test
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## MEKTOVI

---

### Products Affected

- MEKTOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of unresectable or metastatic malignant melanoma with documented BRAF V600E or V600K mutation as detected by an FDA-approved test used in combination with encorfenib
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a oncologist
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## METHYLPHENIDATES

### Products Affected

- DAYTRANA TRANSDERMAL PATCH 15 MG/9HR
- methylphenidate hcl er (cd)
- methylphenidate hcl er (la)
- methylphenidate hcl er oral tablet extended release 10 mg, 20 mg, 72 mg
- methylphenidate hcl er oral tablet extended release 24 hour
- methylphenidate hcl oral solution
- methylphenidate hcl oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	MAOI concurrent use or within the last 14 days
Required Medical Information	Sleep studies for narcolepsy diagnosis
Age Restrictions	6 years of age and older
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Consider benefits of use versus the potential risks of serious cardiovascular events.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## MIGLUSTAT

---

### Products Affected

- *miglustat*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of mild to moderate type 1 Gaucher disease and patient is not a candidate for enzyme replacement therapy.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## MODAFINIL

### Products Affected

- *modafinil*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of excessive sleepiness associated with obstructive sleep apnea (OSA)/hypopnea syndrome OR Diagnosis of excessive sleepiness associated with narcolepsy and patient has tried, is unable to tolerate, or has contraindication(s) to at least one other central nervous system stimulant (e.g., methylphenidate, mixed amphetamine salts, dextroamphetamine) OR Diagnosis of excessive sleepiness associated with shift work disorder
<b>Age Restrictions</b>	17 years of age or older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## MS INTERFERONS

### Products Affected

- AVONEX
- AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT
- AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT
- BETASERON SUBCUTANEOUS KIT
- PLEGRIDY
- PLEGRIDY STARTER PACK

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Diagnosis of relapsing form of multiple sclerosis OR diagnosis of first clinical episode and MRI features consistent with multiple sclerosis.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	For renewal, patient has experienced an objective response to therapy (i.e. no or slowed progression of disease)

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## NATPARA

---

### Products Affected

- NATPARA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of hypocalcemia in patients with hypoparathyroidism
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Prescriber is certified in the NATPARA REMS program
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## NERLYNX

---

### Products Affected

- NERLYNX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of early stage HER2- overexpressed breast cancer. Must be used after trastuzumab therapy.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## NEULASTA

### Products Affected

- NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Treatment for febrile neutropenia, known hypersensitivity to filgrastim, use in the period 14 days before and 24 hours after administration of chemotherapy, use in patients with myeloid malignancy, use to increase the chemotherapy dose intensity or dose schedule beyond established regimens.
Required Medical Information	For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy: Neulasta may be used for the prevention of chemotherapy-induced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia. Patients at low risk (less than 10%) for developing febrile neutropenia may also receive Neulasta prophylaxis if there is a significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease. All patients must receive baseline and regular monitoring of complete blood counts and platelet counts.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## NEUPOGEN

### Products Affected

- NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML
- NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE
- ZARXIO

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Administration within 24 hours preceding or following chemotherapy or radiotherapy, E coli hypersensitivity. For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule beyond established regimen. For treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle.
Required Medical Information	For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy: Neupogen or Zarxio may be used for the prevention of chemotherapy-induced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia. Patients at low risk (less than 10%) for developing febrile neutropenia may receive Neupogen or Zarxio for prophylaxis if there is a significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease. Neupogen or Zarxio is allowable for the treatment of febrile neutropenia in patients who have received prophylaxis with Neupogen or Zarxio (or Leukine) OR in patients at risk for infection-related complications. All patients must receive baseline and regular monitoring of complete blood counts and platelet counts.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 months
Other Criteria	None

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## NINLARO

---

### Products Affected

- NINLARO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of multiple myeloma with documentation of combination therapy with lenalidomide and dexamethasone. Must also have a history of at least 1 prior therapy.
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a hematologist/oncologist.
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## NORTHERA

---

### Products Affected

- NORTHERA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Request will be approved for the following indication(s): orthostatic dizziness, light-headedness, or the feeling that you are about to black out in adults with neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (i.e., Parkinson disease, multiple system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy).
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## NUCALA

---

### Products Affected

- NUCALA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of severe asthma (eosinophilic phenotype) OR eosinophilic granulomatosis with polyangiitis (EGPA)
<b>Age Restrictions</b>	12 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by pulmonologist or immunologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## NUEDEXTA

---

### Products Affected

- NUEDEXTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Patient diagnosis of pseudobulbar affect.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## NUPLAZID

---

### Products Affected

- NUPLAZID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of Parkinson disease psychosis including hallucinations and/or delusions
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## OCTREOTIDE

---

### Products Affected

- *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	None
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## OPSUMIT

---

### Products Affected

- OPSUMIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Pregnancy
<b>Required Medical Information</b>	Diagnosis of pulmonary arterial hypertension WHO group I AND diagnosis was confirmed by right heart catheterization AND female patients are enrolled in the OPSUMIT REMS program.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or cardiologist.
<b>Coverage Duration</b>	6 months - initial. 12 months - renewal
<b>Other Criteria</b>	IUD or two appropriate contraceptive methods will be used for women of childbearing potential.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ORILISSA

---

### Products Affected

- ORILISSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	Pregnancy, known osteoporosis, severe hepatic impairment, current use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors
<b>Required Medical Information</b>	Diagnosis of endometriosis with moderate to severe pain
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Initial: 6 months, Renewal: 12 months, Total: 24 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ORKAMBI

---

### Products Affected

- ORKAMBI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Initial Therapy: Must have diagnosis of cystic fibrosis (CF) with documented homozygous F508del mutation confirmed by FDA-approved CF mutation test. Continuation of therapy: Documentation patient is tolerating and responding to medication (i.e., improved FEV1, weight gain, decreased exacerbations, etc.)
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Must be prescribed by, or in conjunction with, a pulmonologist or is from a CF center accredited by the Cystic Fibrosis Foundation
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## OSPHENA

### Products Affected

- OSPHENA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Vaginal bleeding or dysfunctional uterine bleeding of an undetermined origin, known or suspected estrogen-dependent neoplasia, acute thromboembolism or a past history of thromboembolic disease (including patients with a history of DVT, pulmonary embolism, retinal vein thrombosis, stroke, or myocardial infarction, known or suspected pregnancy.
<b>Required Medical Information</b>	Diagnosis of moderate to severe dyspareunia or atrophic vaginitis due to menopause.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## OXANDROLONE

---

### Products Affected

- *oxandrolone oral*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Known or suspected carcinoma of the prostate or breast (in male patients), carcinoma of the breast in women with hypercalcemia, pregnancy, nephrosis (the nephrotic phase of nephritis), hypercalcemia.
<b>Required Medical Information</b>	None
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## PCSK9 INHIBITOR

### Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR
- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	FOR PRALUENT: MUST MEET CRITERIA #1 OR #3. FOR REPATHA: MUST MEET CRITERIA #1, #2 OR #3. 1. Diagnosis of heterozygous familial hypercholesterolemia (HeFH) confirmed by genotyping OR Simon Broome criteria: Total cholesterol greater than 290mg/dL or LDL cholesterol greater than 190mg/dL, PLUS ONE OF THE FOLLOWING: Tendon xanthomas in patient, or 1st degree relative (parent, sibling, child), or 2nd degree relative (grandparent, uncle, aunt) OR DNA-based evidence of LDL receptor mutation, familial defective apo B-100, or PCSK9 mutation 2a. Myocardial infarction prophylaxis, stroke prophylaxis, and to reduce risk of coronary revascularization in patients with established CVD OR 2b. Diagnosis of homozygous familial hypercholesterolemia (HoFH) confirmed by genotyping OR diagnosis based on the following: a. History of untreated LDL-C greater than 500 mg/dL AND xanthoma before 10 years of age OR b. Documentation of HeFH in both parents 3. Diagnosis of clinical atherosclerotic cardiovascular disease (CVD) as defined as one of the following: a. acute coronary syndrome, b. history of myocardial infarction, c. stable/unstable angina, d. coronary or other arterial revascularization, e. stroke, f. transient ischemic stroke (TIA), g. peripheral arterial disease presumed to be atherosclerotic region. AND MEETS CRITERIA #4, #5, and #6, 4. Provide baseline and current LDL-C 5. LDL-C greater than or equal to 70 mg/dL 6. Used in combination with maximally tolerated high-intensity statin OR MEETS CRITERIA #7 AND #8. 7. Statin intolerant 8. LDL-C greater than or equal to 70 mg/dL CONTINUING THERAPY: 1. Documented response to Praluent or Repatha, defined as ONE of the following: a. The patient is tolerating medication b. Will continue to be used in combination with maximally tolerated statin (unless statin intolerant).

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019

# CARE N' CARE HEALTH PLAN

## 2019 Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	Repatha: 13 years of age or older for diagnosis HoFM, Diagnosis CVD or HeFH AND Praluent or Repatha : 18 years of age or older
<b>Prescriber Restrictions</b>	Must be prescribed by, or in consultation with, a cardiologist, endocrinologist, or lipid specialist
<b>Coverage Duration</b>	Initial approval: 8 weeks, Renewal approval: Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## PEGASYS

### Products Affected

- PEGASYS PROCLICK  
SUBCUTANEOUS SOLUTION 180  
MCG/0.5ML
- PEGASYS SUBCUTANEOUS  
SOLUTION

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Decompensated liver disease. Autoimmune hepatitis. Concomitant administration of didanosine with ribavirin in patients coinfecting with HIV.
Required Medical Information	Chronic hepatitis B: Diagnosis of chronic hepatitis B infection and patient is without decompensated liver disease. Chronic Hepatitis C: Criteria will be applied consistent with current AASLD-IDSA guidance
Age Restrictions	HCV: 18 years of age or older if used as triple therapy, otherwise 5 years of age or older. Hepatitis B: 3 years of age or older.
Prescriber Restrictions	ID specialist, Gastroenterologist, Oncologist
Coverage Duration	HCV:12 weeks to 72 weeks total depending on genotype and initial vs. renewal therapy. HBV:48 weeks.
Other Criteria	Monitor for evidence of depression.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## POMALYST

### Products Affected

- POMALYST

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Documentation of ALL of the following: 1. Disease has progressed within 60 days of completion of the last therapy 2. If female of reproductive potential ALL of the below: Two negative pregnancy tests obtained prior to initiating therapy with Pomalyst, monthly negative pregnancy tests during therapy 3. Patient has been counseled about the use of 2 forms of reliable contraception before, during, and 1 month after discontinuing therapy with Pomalyst 4. Patient assessment to determine if prophylactic aspirin or antithrombic treatment (warfarin, clopidogrel) will need to be taken to reduce the risk of VTE (embolism, stroke) 5. Registered and certified to be compliant with Pomalyst REMS (Risk Evaluation and Mitigation Strategy) program
Age Restrictions	None
Prescriber Restrictions	Oncologist or hematologist
Coverage Duration	12 months
Other Criteria	A documented diagnosis of multiple myeloma who have received at least two prior therapies including lenalidomide (Revlimid) and a proteasome inhibitor with disease progression on or within 60 days of last therapy. Also used in combination with dexamethasone (per Micromedex app).

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## PROMACTA

### Products Affected

- PROMACTA ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	For new starts, at the time of diagnosis of ITP or hepatitis C infection associated thrombocytopenia, one of the following are required: 1) a pretreatment platelet count less than 30,000/microL or 2) a platelet count less than or equal to 50,000/microL with significant mucous membrane bleeding or risk factors for bleeding. Patients must be evaluated for other causes of thrombocytopenia and have had an insufficient response or intolerance to corticosteroids, or immunoglobulins, or splenectomy. For continuation of therapy, one of the following are required: 1) an increase in platelet count to greater than or equal to 50,000/microL or 2) an increase in platelet level that is sufficient to avoid clinically important bleeding after at least 4 weeks of Promacta at the maximum dose. For all patients receiving Promacta therapy, if platelets increase above 200,000/microL, therapy will be adjusted to maintain the minimal platelet count needed to reduce the risk for bleeding. Liver function must be assessed pretreatment and regularly throughout therapy. To continue Promacta therapy, alanine aminotransferase levels must not be greater than or equal to 3 times the upper limit of normal with any of the following characteristics: progressive, persistent, accompanied by increased bilirubin or symptoms of liver injury or evidence of hepatic decompensation.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	6 month initial, 12 month renewal if adequate platelet response, 3 month w/o platelet response
Other Criteria	None

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## REGRANEX

---

### Products Affected

- REGRANEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diabetic Neuropathic Ulcers: Diabetic patient with ulcer wound. Treatment will be given in combination with ulcer wound care (e.g., debridement, infection control, and/or pressure relief).
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Diabetic Neuropathic Ulcers: Maximum 5 months.
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## REVLIMID

### Products Affected

- REVLIMID

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Pregnancy
Required Medical Information	Diagnosis of one of the following 1) multiple myeloma and medication will be used in combination with dexamethasone 2) autologous hematopoietic stem-cell transplantation (HSCT) in multiple myeloma patients 3) transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities 4) mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib AND patient is enrolled in the Revlimid REMS Program
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Male and female patients of child-bearing potential should be instructed on the importance of proper utilization of appropriate contraceptive methods for Revlimid use. Patients should be monitored for signs and symptoms of thromboembolism.



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## RUBRACA

### Products Affected

- RUBRACA

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Diagnosis of 1. deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer and all of the following criteria (A-E): A. BRCA mutation positive as detected by an approved FDA laboratory test, B. Previous trial/failure with two or more chemotherapy regimens, C. Used as monotherapy, D. Agreement of provider to perform a complete blood count (CBC) at baseline and monthly thereafter, E. Women of reproductive potential must use an effective method of contraception during therapy and for 6 months after the last dose. OR 2. recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and all of the following (A-D): A. Complete or partial response to platinum-based chemotherapy B. Used as monotherapy C. Agreement of provider to perform a complete blood count (CBC) at baseline and monthly thereafter, D. Women of reproductive potential must use an effective method of contraception during therapy and for 6 months after the last dose.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Hematologist or Oncologist
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## RYDAPT

### Products Affected

- RYDAPT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Angioedema
<b>Required Medical Information</b>	Diagnosis of treatment naive FLT3 mutation-positive acute myelogenous leukemia (AML) AND Must be used in combination with standard cytarabine and daunorubicin induction and consolidation therapy OR Diagnosis of systemic mastocytosis
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a oncologist
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## SAMSCA

### Products Affected

- SAMSCA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Patients with anuria, patients requiring an urgent increase in serum sodium, patients unable to sense and respond to thirst, concomitant use of a strong CYP 3A inhibitor (e.g., clarithromycin, ketoconazole).
<b>Required Medical Information</b>	Treatment with Samsca is being initiated or re-initiated in a hospital where serum sodium can be monitored closely
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	30 days
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## SILDENAFIL

### Products Affected

- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Nitrate therapy
Required Medical Information	Diagnosis of pulmonary arterial hypertension that was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.) AND Patient has WHO Group I PAH
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## SOMATULINE DEPOT

### Products Affected

- SOMATULINE DEPOT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis for use: 1) Acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option, 2) unresectable, well- or moderately-differentiated, locally advanced or metastatic carcinoid gastroenteropancreatic neuroendocrine tumor, 3) treatment of hyperthyroidism secondary to thyrotropinoma, 4) carcinoid syndrome.
<b>Age Restrictions</b>	Adults: 18 years and older.
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Initial approval: 3 months. Extended approval: 3 months with dose adjusted according to response
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## SOMAVERT

---

### Products Affected

- SOMAVERT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	IV administration of Somavert, concomitant use of Sandostatin or Somatuline.
<b>Required Medical Information</b>	Diagnosis of acromegaly was confirmed by an elevated IGF-1 level or elevated GH level with a glucose tolerance test. Patient has tried and failed at least a 3 month trial of Sandostatin or Somatuline. For renewal, reduction in IGF-1 level from baseline.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## SPRYCEL

### Products Affected

- SPRYCEL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of one of the following 1) Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, 2) Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, 3) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## STIVARGA

### Products Affected

- STIVARGA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	A documented diagnosis of metastatic colorectal cancer AND documentation of prior therapy with ALL of the following per the indication: 1. (fluoropyrimidine-, oxaliplatin-, and irinotecan)-based chemotherapy 2. bevacizumab (Avastin) 3. panitumumab (Vectibix) OR cetuximab (Erbix) (for KRAS mutation-negative patients only) OR a documented diagnosis of locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate (Gleevec) and sunitinib malate (Sutent) OR a documented diagnosis of hepatocellular carcinoma in patients previously treated with sorafenib (Nexavar).
Age Restrictions	18 years of age or older
Prescriber Restrictions	Oncologist
Coverage Duration	Plan Year
Other Criteria	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## SUTENT

### Products Affected

- SUTENT

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Renal cell carcinoma: Diagnosis of advanced or metastatic renal cell carcinoma OR adjuvant treatment in renal cell carcinoma for patients at high risk of recurrence following nephrectomy. Gastrointestinal stromal tumor (GIST): Diagnosis of GIST after disease progression on or intolerance to Gleevec (imatinib). Pancreatic neuroendocrine tumors: Diagnosis of progressive, well-differentiated pancreatic neuroendocrine tumor that is unresectable locally advanced or metastatic disease.
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## SYLATRON

---

### Products Affected

- SYLATRON SUBCUTANEOUS KIT  
200 MCG, 300 MCG, 600 MCG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Autoimmune hepatitis. Hepatic decompensation (Child-Pugh score greater than 6 [Class B or C])
<b>Required Medical Information</b>	Melanoma: Diagnosis of melanoma with microscopic or gross nodal involvement AND The prescribed medication will be used as adjuvant therapy within 84 days of definitive surgical resection, including complete lymphadenectomy.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## SYMDEKO

---

### Products Affected

- SYMDEKO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of cystic fibrosis and patient is homozygous for the F508del mutation OR has mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor verified by an FDA-approved CF mutation test.
<b>Age Restrictions</b>	12 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Initial - 6 months. Renewal - 12 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## SYMLIN

### Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Severe hypoglycemia that required assistance during the past 6 months, gastroparesis, patient requires drug therapy to stimulate gastrointestinal motility, the presence of hypoglycemia unawareness (i.e., inability to detect and act upon the signs or symptoms of hypoglycemia).
Required Medical Information	None
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	The patient must have inadequate glycemic control (HbA1c greater than 7% but less than 9%) at initiation of therapy, patient currently receiving optimal mealtime insulin therapy. If taking Symlin in previous 6 months, patient demonstrated a reduction in HbA1c since initiating Symlin therapy

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TAFINLAR

---

### Products Affected

- TAFINLAR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of unresectable or metastatic malignant melanoma with documented positive BRAF V600E mutation as detected by an FDA-approved test
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	Tafinlar should not be used in patients with wild-type BRAF melanoma due to the potential risk of tumor promotion in these patients.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TAGRISSO

---

### Products Affected

- TAGRISSO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of metastatic EGFR mutation-positive, non-small cell lung cancer (NSCLC) OR metastatic, non-small cell lung cancer with confirmed presence of T790M EGFR mutation AND whose disease has progressed on or after EGFR tyrosine kinase inhibitor based therapy. Diagnosis confirmed by an FDA-approved test.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TAKHZYRO

---

### Products Affected

- TAKHZYRO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of hereditary angioedema and used for prophylaxis
<b>Age Restrictions</b>	12 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TALZENNA

---

### Products Affected

- TALZENNA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	None
Required Medical Information	Diagnosis of deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a oncologist
Coverage Duration	Plan year
Other Criteria	None



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TASIGNA

---

### Products Affected

- TASIGNA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in the chronic phase OR Diagnosis of Ph+ CML in the chronic or accelerated phase with resistance or intolerance to prior therapy
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TECFIDERA

---

### Products Affected

- TECFIDERA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of relapsing forms of multiple sclerosis (relapsing-remitting MS or progressive-relapsing MS, or secondary-progressive MS) OR patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	For renewal, Patient had an objective response to therapy (ie no or slowed progression of disease)

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TESTOSTERONES

### Products Affected

- *testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*
- *testosterone transdermal solution*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Female, prostate cancer, breast cancer.
<b>Required Medical Information</b>	Before the start of testosterone therapy patient has (or patient currently has) a confirmed low testosterone level (i.e. total testosterone less than 300 ng/dL, free or bioavailable, testosterone less than 5 ng/dL) or absence of endogenous testosterone.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TETRABENAZINE

### Products Affected

- *tetrabenazine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Patients with untreated or inadequately treated depression or who are actively suicidal, history of hepatic disease, use in combination with MAO inhibitors or reserpine (or it has been less than 20 days since reserpine was discontinued).
<b>Required Medical Information</b>	None
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## THALOMID

### Products Affected

- THALOMID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Pregnancy
<b>Required Medical Information</b>	Diagnosis of multiple myeloma that is newly diagnosed and is receiving concurrent dexamethasone OR of Acute treatment of cutaneous manifestations of moderate/severe erythema nodosum leprosum AND medication will not be used as monotherapy in the presence of moderate to severe neuritis OR Maintenance treatment for prevention/suppression of cutaneous manifestations of erythema nodosum leprosum recurrence
<b>Age Restrictions</b>	12 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or infectious disease specialist.
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	Patients are monitored for signs and symptoms of thromboembolism. Male and female patients of child-bearing potential are instructed on the importance of proper utilization of appropriate contraceptive methods.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TIBSOVO

---

### Products Affected

- TIBSOVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of acute myeloid leukemia in relapsed or refractory patients, with susceptible isocitrate dehydrogenase-1 mutation
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or hematologist
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TRACLEER

### Products Affected

- TRACLEER

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Receiving concomitant cyclosporine A or glyburide therapy. Aminotransferase elevations are accompanied by signs or symptoms of liver dysfunction or injury or increases in bilirubin at least 2 times the upper limit of normal.
<b>Required Medical Information</b>	Diagnosis of pulmonary arterial hypertension that was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.) AND Patient has WHO Group I PAH AND Patient has New York Heart Association (NYHA) Functional Class II-IV AND pregnancy must be excluded prior to the start of therapy and will be prevented thereafter with two forms of reliable contraception in female patients of reproductive potential.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or cardiologist.
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## TYMLOS

### Products Affected

- TYMLOS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of postmenopausal osteoporosis AND one of the following: 1) Patient has experienced a prior fragility fracture, OR 2) Patient has 2 of the following risk factors for fracture: advanced age, parental history of fracture, low body mass index, current smoker, chronic alcohol use, rheumatoid arthritis, chronic steroid use, or other secondary cause of osteoporosis OR 3) Patient had an inadequate response to an adequate trial of a bisphosphonate (one year) or patient has a contraindication or intolerance to bisphosphonate trial.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## UPTRAVI

---

### Products Affected

- UPTRAVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of pulmonary arterial hypertension (WHO Group 1) confirmed by right heart catheterization AND patient has tried and had an insufficient response to at least one other PAH agent (e.g., sildenafil) therapy.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or cardiologist.
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## VENCLEXTA

---

### Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	CLL for patients with 17p deletion and have had at least 1 prior therapy
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## VERZENIO

### Products Affected

- VERZENIO

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	BREAST CANCER (1) Patient must have a diagnosis of advanced or metastatic breast cancer AND (2a) must be used in combination with fulvestrant for the treatment of disease progression following endocrine therapy OR (2b) used as monotherapy for treatment of disease progression following endocrine therapy and patient has already received at least one prior chemotherapy regimen of Ibrance or Kisqali OR (2c) used as initial endocrine-based treatment in combination with an aromatase inhibitor AND (3) disease is hormone receptor positive AND human epidermal growth factor 2 (HER2)- negative
Age Restrictions	18 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Plan Year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## VIZIMPRO

---

### Products Affected

- VIZIMPRO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of metastatic non-small cell lung cancer with confirmed epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a oncologist
<b>Coverage Duration</b>	Plan year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## XALKORI

---

### Products Affected

- XALKORI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Supporting statement of diagnosis from the physician that establishes the metastatic cancer as anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer (NSCLC)
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## XELJANZ

### Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Psoriatic arthritis (PsA) or Rheumatoid arthritis (RA) (Initial): Diagnosis of psoriatic arthritis or moderately to severely active RA and an inadequate response or intolerance to methotrexate. One of the following: Failure, contraindication, or intolerance to Enbrel (etanercept) OR Humira (adalimumab), OR patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-IV-TR 300.29 for specific phobia diagnostic criteria), OR for continuation of prior tofacitinib therapy. Patient is not receiving tofacitinib in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab)]. Patient is not receiving tofacitinib in combination with a potent immunosuppressant (eg, azathioprine, cyclosporine). Ulcerative Colitis (UC) (Initial): Diagnosis of moderately to severely active UC. Patient is corticosteroid dependent (ie, an inability to successfully taper corticosteroids without a return of the symptoms of UC), OR history of failure, contraindication, or intolerance to one of the following: oral aminosalicylate, oral corticosteroid, azathioprine, 6-mercaptopurine AND one of the following: failure, contraindication, or intolerance to Humira (adalimumab).
Age Restrictions	None
Prescriber Restrictions	Prescribed by or in consultation with a rheumatologist or gastroenterologist.
Coverage Duration	Plan Year
Other Criteria	Reauthorization: Documentation of positive clinical response to tofacitinib therapy. Patient is not receiving tofacitinib in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab)]. Patient is not

Formulary ID 19516, Ver 7  
Last Updated 1/23/2019  
Effective 2/1/2019

# CARE N' CARE HEALTH PLAN

## 2019 Prior Authorization Criteria

PA Criteria	Criteria Details
	receiving tofacitinib in combination with a potent immunosuppressant (eg, azathioprine, cyclosporine).

## XGEVA

### Products Affected

- XGEVA

PA Criteria	Criteria Details
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	Uncorrected hypocalcemia
<b>Required Medical Information</b>	1.) Patient has bone metastases from a solid tumor. OR 2.) Patient has or giant cell tumor of the bone that is unresectable or where surgical resection is likely to result in severe morbidity. OR 3.) Patient has hypercalcemia of malignancy refractory to bisphosphonate therapy. OR 4.) Prevention of skeletal related events in patient with multiple myeloma.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## XOLAIR

### Products Affected

- XOLAIR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of moderate to severe persistent allergic asthma AND Evidence of specific allergic sensitivity confirmed by positive skin test (i.e. prick/puncture test) or blood test (i.e. radioallergosorbent test) for a specific IgE or in vitro reactivity to a perennial aeroallergen AND Pretreatment serum IgE levels greater than 30 and less than 1300 IU/mL AND Symptoms are not adequately controlled with maximally tolerated dose of inhaled corticosteroid (ICS) plus long-acting beta2-agonist (LABA) for at least 3 months OR documented intolerance to inhaled corticosteroid (ICS) plus long-acting beta2 agonist(LABA), OR contraindication to inhaled corticosteroid (ICS) plus long-acting beta2 agonist(LABA) OR diagnosis of chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment.
<b>Age Restrictions</b>	6 years of age and older
<b>Prescriber Restrictions</b>	Asthma specialist (i.e., allergist, immunologist, or pulmonologist) or dermatologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	To continue therapy, patients must demonstrate an improvement in asthma control with use of Xolair.



# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## XTANDI

---

### Products Affected

- XTANDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of metastatic castration-resistant prostate cancer AND the patient has tried and had an inadequate response, contraindication or intolerance to Zytiga.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed or in consultation with an oncologist or urologist
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## XURIDEN

---

### Products Affected

- XURIDEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of Hereditary orotic aciduria.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## XYREM

### Products Affected

- XYREM

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	If the patient is taking/receiving any of the following: anxiolytics, sedatives, hypnotics, barbiturates, benzodiazepines or ethanol.
<b>Required Medical Information</b>	A. The diagnosis is documented as excessive daytime sleepiness OR the diagnosis is documented as cataplexy (a condition characterized by weak or paralyzed muscles) in patients with narcolepsy. C. AND if the patient has received prior treatment with Xyrem, the patient must experience a decrease in daytime sleepiness and/or cataplexy in a narcoleptic patient.
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## YONSA

---

### Products Affected

- YONSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	A) Diagnosis of metastatic castration-resistant prostate cancer, and used in combination with methylprednisolone, B) Documented history of trial with, inadequate treatment response, adverse event, or contraindication to Zytiga.
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or urologist
<b>Coverage Duration</b>	Plan Year
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ZEJULA

---

### Products Affected

- ZEJULA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	Diagnosis of recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer AND patient had a complete or partial response to platinum-based chemotherapy
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a oncologist or gynecologist
Coverage Duration	Plan year
Other Criteria	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ZYKADIA

---

### Products Affected

- ZYKADIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All medically accepted indications not otherwise excluded from Part D.
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	Diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
<b>Age Restrictions</b>	None
<b>Prescriber Restrictions</b>	None
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	None

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## ZYTIGA

### Products Affected

- *abiraterone acetate*
- ZYTIGA ORAL TABLET 500 MG

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	None
Required Medical Information	None
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Plan Year
Other Criteria	Used in combination with prednisone.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## PART B VERSUS PART D

---

### Products Affected

- ABELCET
- *acetylcysteine inhalation*
- *acyclovir sodium intravenous solution*
- *albuterol sulfate inhalation*
- AMBISOME
- AMINOSYN II INTRAVENOUS SOLUTION 10 %, 8.5 %
- AMINOSYN II/ELECTROLYTES
- AMINOSYN/ELECTROLYTES
- AMINOSYN-HBC
- AMINOSYN-PF
- AMINOSYN-RF
- *amphotericin b injection*
- *aprepitant*
- ASTAGRAF XL
- AZASAN
- *azathioprine oral*
- *budesonide inhalation*
- *calcitonin (salmon)*
- *caspofungin acetate*
- *chlorpromazine hcl oral tablet 10 mg, 25 mg*
- CLINIMIX E/DEXTROSE (2.75/10)
- CLINIMIX E/DEXTROSE (2.75/5)
- CLINIMIX E/DEXTROSE (4.25/10)
- CLINIMIX E/DEXTROSE (4.25/25)
- CLINIMIX E/DEXTROSE (4.25/5)
- CLINIMIX E/DEXTROSE (5/15)
- CLINIMIX E/DEXTROSE (5/20)
- CLINIMIX E/DEXTROSE (5/25)
- CLINIMIX/DEXTROSE (4.25/10)
- CLINIMIX/DEXTROSE (4.25/25)
- CLINIMIX/DEXTROSE (4.25/5)
- CLINIMIX/DEXTROSE (5/15)
- CLINIMIX/DEXTROSE (5/20)
- CLINIMIX/DEXTROSE (5/25)
- CLINISOL SF
- *colistimethate sodium (cba)*
- *cromolyn sodium inhalation*
- *cyclophosphamide oral capsule*
- *cyclosporine modified*
- *cyclosporine oral capsule*
- DEPO-PROVERA INTRAMUSCULAR SUSPENSION 400 MG/ML
- *dextrose intravenous solution 10 %, 5 %*
- *diphtheria-tetanus toxoids dt*
- *duramorph*
- ELIGARD
- ENGERIX-B INJECTION SUSPENSION 10 MCG/0.5ML, 20 MCG/ML
- ENVARSUS XR
- FIRMAGON
- FREAMINE HBC
- GENGRAF ORAL CAPSULE 100 MG, 25 MG
- GENGRAF ORAL SOLUTION
- *granisetron hcl oral*
- HEPATAMINE
- IMOVAX RABIES
- INTRALIPID
- INTRON A
- *ipratropium bromide inhalation*
- *ipratropium-albuterol*
- *levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/0.5ml, 1.25 mg/3ml*
- *levocarnitine oral solution*
- *levocarnitine oral tablet*
- *methotrexate oral*
- *methotrexate sodium (pf) injection solution 50 mg/2ml*
- *methotrexate sodium injection solution 250 mg/10ml*
- *mycophenolate mofetil*
- *mycophenolate sodium*
- NEBUPENT
- NEPHRAMINE
- *nutrilipid intravenous emulsion 20 %*
- *ondansetron*
- *ondansetron hcl oral*
- PLENAMINE
- PREMASOL
- PROCALAMINE
- PROSOL



# CARE N' CARE HEALTH PLAN

## 2019 Prior Authorization Criteria

- PULMOZYME
- RABAVERT
- RAPAMUNE ORAL SOLUTION
- RECOMBIVAX HB
- SANDIMMUNE ORAL SOLUTION
- SENSIPAR
- *sirolimus oral*
- *tacrolimus oral*
- TENIVAC
- *tetanus-diphtheria toxoids td*
- *tigecycline*
- *tobramycin inhalation*
- TPN ELECTROLYTES INTRAVENOUS SOLUTION
- TRAVASOL
- TRELSTAR MIXJECT
- TREXALL
- TROPHAMINE INTRAVENOUS SOLUTION 10 %
- TWINRIX
- XATMEP
- ZORTRESS

### Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

# CARE N' CARE HEALTH PLAN

2019 Prior Authorization Criteria

## Index

### A

ABELCET.....	152
abiraterone acetate .....	151
acetylcysteine inhalation.....	152
ACTIMMUNE.....	1
acyclovir sodium intravenous solution ...	152
ADEMPAS .....	2
albuterol sulfate inhalation.....	152
ALECENSA.....	3
ALUNBRIG.....	5
AMBISOME.....	152
AMINOSYN II INTRAVENOUS SOLUTION 10 %, 8.5 % .....	152
AMINOSYN II/ELECTROLYTES.....	152
AMINOSYN/ELECTROLYTES .....	152
AMINOSYN-HBC .....	152
AMINOSYN-PF .....	152
AMINOSYN-RF.....	152
amitriptyline hcl oral.....	49
amphetamine-dextroamphet er.....	6
amphotericin b injection .....	152
aprepitant.....	152
ARCALYST .....	7
ARIKAYCE.....	8
armodafinil.....	9
ASCOMP-CODEINE .....	47
ASTAGRAF XL.....	152
AUBAGIO .....	10
AURYXIA .....	11
AUSTEDO.....	12
AVONEX.....	90
AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT.....	90
AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT.....	90
AZASAN .....	152
azathioprine oral.....	152

### B

benztropine mesylate oral .....	52
BETASERON SUBCUTANEOUS KIT ..	90
BIVIGAM INTRAVENOUS SOLUTION 10 GM/100ML.....	71

BOSULIF.....	13
BRAFTOVI.....	14
budesonide inhalation .....	152
butalbital-apap-caff-cod oral capsule 50- 325-40-30 mg.....	47
butalbital-apap-caffeine oral tablet 50-325- 40 mg .....	47
butalbital-asa-caff-codeine.....	47
butalbital-aspirin-caffeine oral capsule.....	47
<b>C</b>	
CABOMETYX .....	15
calcitonin (salmon).....	152
CALQUENCE .....	16
carbinoxamine maleate oral solution .....	51
carbinoxamine maleate oral tablet 4 mg ...	51
CARIMUNE NF INTRAVENOUS SOLUTION RECONSTITUTED 6 GM .....	71
casprofungin acetate.....	152
CAYSTON.....	17
chlorpromazine hcl oral tablet 10 mg, 25 mg .....	152
chlorzoxazone oral tablet 500 mg.....	60
clemastine fumarate oral tablet 2.68 mg ...	51
CLIMARA PRO .....	57
CLINIMIX E/DEXTROSE (2.75/10).....	152
CLINIMIX E/DEXTROSE (2.75/5).....	152
CLINIMIX E/DEXTROSE (4.25/10).....	152
CLINIMIX E/DEXTROSE (4.25/25).....	152
CLINIMIX E/DEXTROSE (4.25/5).....	152
CLINIMIX E/DEXTROSE (5/15).....	152
CLINIMIX E/DEXTROSE (5/20).....	152
CLINIMIX E/DEXTROSE (5/25).....	152
CLINIMIX/DEXTROSE (4.25/10) .....	152
CLINIMIX/DEXTROSE (4.25/25) .....	152
CLINIMIX/DEXTROSE (4.25/5) .....	152
CLINIMIX/DEXTROSE (5/15) .....	152
CLINIMIX/DEXTROSE (5/20) .....	152
CLINIMIX/DEXTROSE (5/25) .....	152
CLINISOL SF.....	152
clomipramine hcl oral .....	49
colistimethate sodium (cba) .....	152
COMBIPATCH .....	57

# CARE N' CARE HEALTH PLAN

## 2019 Prior Authorization Criteria

COPIKTRA.....	18	estradiol oral.....	57
CORLANOR.....	19	estradiol transdermal.....	57
COTELLIC.....	20	estradiol-norethindrone acet.....	57
cromolyn sodium inhalation.....	152	estropipate oral tablet 0.75 mg.....	57
cyclobenzaprine hcl oral.....	60	eszopiclone.....	59
cyclophosphamide oral capsule.....	152	EVAMIST.....	57
cyclosporine modified.....	152	EXJADE.....	33
cyclosporine oral capsule.....	152	<b>F</b>	
cyproheptadine hcl oral.....	51	FARYDAK.....	34
CYSTARAN.....	21	fentanyl citrate buccal.....	35
<b>D</b>		FIRMAGON.....	152
dalfampridine er.....	22	FLEBOGAMMA DIF INTRAVENOUS	
DAYTRANA TRANSDERMAL PATCH		SOLUTION 5 GM/50ML.....	71
15 MG/9HR.....	87	FORTEO SUBCUTANEOUS SOLUTION	
DEPO-PROVERA INTRAMUSCULAR		600 MCG/2.4ML.....	36
SUSPENSION 400 MG/ML.....	152	FREAMINE HBC.....	152
dextroamphetamine sulfate er.....	6	FYAVOLV.....	57
dextroamphetamine sulfate oral tablet.....	6	<b>G</b>	
dextrose intravenous solution 10 %, 5 %	152	GALAFOLD.....	37
diclofenac sodium transdermal gel 3 % ....	23	GAMMAGARD INJECTION SOLUTION	
diphtheria-tetanus toxoids dt.....	152	2.5 GM/25ML.....	71
dipyridamole oral.....	58	GAMMAGARD S/D LESS IGA.....	71
disopyramide phosphate oral.....	48	GAMMAKED INJECTION SOLUTION 1	
DIVIGEL TRANSDERMAL GEL 1		GM/10ML.....	71
MG/GM.....	57	GAMMAPLEX INTRAVENOUS	
doxepin hcl oral.....	49	SOLUTION 10 GM/100ML, 10	
dronabinol.....	24	GM/200ML, 20 GM/200ML, 5	
DUAVEE.....	57	GM/50ML.....	71
duramorph.....	152	GAMUNEX-C INJECTION SOLUTION 1	
<b>E</b>		GM/10ML.....	71
ELIGARD.....	152	GENGRAF ORAL CAPSULE 100 MG, 25	
ENBREL SUBCUTANEOUS SOLUTION		MG.....	152
PREFILLED SYRINGE.....	25, 26	GENGRAF ORAL SOLUTION.....	152
ENBREL SUBCUTANEOUS SOLUTION		GILENYA ORAL CAPSULE 0.5 MG.....	38
RECONSTITUTED.....	25, 26	GILOTRIF.....	39
ENBREL SURECLICK SUBCUTANEOUS		glatiramer acetate.....	40
SOLUTION AUTO-INJECTOR ....	25, 26	GOCOVRI.....	41
ENDARI.....	27	granisetron hcl oral.....	152
ENGERIX-B INJECTION SUSPENSION		guanfacine hcl oral.....	46
10 MCG/0.5ML, 20 MCG/ML.....	152	<b>H</b>	
ENTRESTO.....	28	HEPATAMINE.....	152
ENVARUSUS XR.....	152	HETLIOZ.....	45
EPIDIOLEX.....	29	HUMIRA PEDIATRIC CROHNS START	
ergoloid mesylates oral.....	55	SUBCUTANEOUS PREFILLED	
ERLEADA.....	30	SYRINGE KIT.....	61, 62
ESBRIET.....	31		

# CARE N' CARE HEALTH PLAN

## 2019 Prior Authorization Criteria

HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT .....	61, 62	LENVIMA 12 MG DAILY DOSE.....	78
HUMIRA PEN-CD/UC/HS STARTER ..	61, 62	LENVIMA 14 MG DAILY DOSE.....	78
HUMIRA PEN-PS/UV/ADOL HS START .....	61, 62	LENVIMA 18 MG DAILY DOSE.....	78
HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT.....	61, 62	LENVIMA 20 MG DAILY DOSE.....	78
hydroxyzine hcl oral syrup.....	50	LENVIMA 24 MG DAILY DOSE.....	78
hydroxyzine hcl oral tablet.....	50	LENVIMA 4 MG DAILY DOSE.....	78
hydroxyzine pamoate oral.....	50	LENVIMA 8 MG DAILY DOSE.....	78
<b>I</b>		LETAIRIS.....	79
IBRANCE.....	63	LEUKINE INTRAVENOUS.....	80
ICLUSIG.....	64	leuprolide acetate injection .....	83
IDHIFA.....	65	levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/0.5ml, 1.25 mg/3ml.....	152
IMBRUVICA.....	66	levocarnitine oral solution.....	152
imipramine hcl oral .....	49	levocarnitine oral tablet.....	152
imipramine pamoate.....	49	lidocaine external patch 5 % .....	81
IMOVAX RABIES .....	152	LORBRENA .....	82
INCRELEX.....	67	LUPRON DEPOT (1-MONTH).....	83
indomethacin er.....	47	LUPRON DEPOT (3-MONTH).....	83
indomethacin oral.....	47	LUPRON DEPOT (4-MONTH).....	83
INTRALIPID .....	152	LUPRON DEPOT (6-MONTH).....	83
INTRAROSA.....	68	LYNPARZA .....	84
INTRON A.....	152	<b>M</b>	
ipratropium bromide inhalation .....	152	MAVYRET.....	44
ipratropium-albuterol .....	152	megestrol acetate oral suspension 40 mg/ml, 625 mg/5ml .....	56
IRESSA.....	69	megestrol acetate oral tablet.....	56
itraconazole oral capsule.....	70	MEKINIST .....	85
<b>J</b>		MEKTOVI .....	86
JINTELI .....	57	MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG.....	57
JUXTAPID .....	72	metaxalone oral tablet 800 mg.....	60
<b>K</b>		methocarbamol oral .....	60
KALYDECO.....	73	methotrexate oral .....	152
KISQALI 200 DOSE .....	74	methotrexate sodium (pf) injection solution 50 mg/2ml .....	152
KISQALI 400 DOSE .....	74	methotrexate sodium injection solution 250 mg/10ml .....	152
KISQALI 600 DOSE .....	74	methylphenidate hcl er (cd) .....	87
KISQALI FEMARA 200 DOSE .....	74	methylphenidate hcl er (1a) .....	87
KISQALI FEMARA 400 DOSE .....	74	methylphenidate hcl er oral tablet extended release 10 mg, 20 mg, 72 mg .....	87
KISQALI FEMARA 600 DOSE .....	74	methylphenidate hcl er oral tablet extended release 24 hour .....	87
KORLYM .....	75	methylphenidate hcl oral solution.....	87
KUVAN .....	76	methylphenidate hcl oral tablet.....	87
KYNAMRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE ..	77		
<b>L</b>			
LENVIMA 10 MG DAILY DOSE.....	78		

# CARE N' CARE HEALTH PLAN

## 2019 Prior Authorization Criteria

miglustat.....	88	PLENAMINE .....	152
modafinil.....	89	POMALYST .....	109
mycophenolate mofetil.....	152	PRALUENT SUBCUTANEOUS	
mycophenolate sodium .....	152	SOLUTION PEN-INJECTOR....	106, 107
<b>N</b>		PREFEST .....	57
NATPARA.....	91	PREMARIN ORAL .....	57
NEBUPENT.....	152	PREMASOL .....	152
NEPHRAMINE .....	152	PREMPHASE.....	57
NERLYNX .....	92	PREMPRO.....	57
NEULASTA SUBCUTANEOUS		PROCALAMINE.....	152
SOLUTION PREFILLED SYRINGE ..	93	PROCRIT.....	32
NEUPOGEN INJECTION SOLUTION 300		PROLASTIN-C INTRAVENOUS	
MCG/ML, 480 MCG/1.6ML .....	94	SOLUTION RECONSTITUTED 1000	
NEUPOGEN INJECTION SOLUTION		MG .....	4
PREFILLED SYRINGE .....	94	PROMACTA ORAL TABLET .....	110
NINLARO.....	95	promethazine hcl oral syrup.....	50
NORDITROPIN FLEXPPO.....	42	promethazine hcl oral tablet.....	50
norethindrone-eth estradiol .....	57	promethazine hcl rectal .....	50
NORPACE CR.....	48	promethazine vc plain oral solution.....	51
NORTHERA.....	96	promethazine-phenylephrine.....	51
NUCALA .....	97	PROSOL .....	152
NUDEXTA.....	98	PULMOZYME .....	153
NUPLAZID.....	99	<b>R</b>	
nutrilipid intravenous emulsion 20 % .....	152	RABAVERT .....	153
<b>O</b>		RAPAMUNE ORAL SOLUTION .....	153
octreotide acetate injection solution 100		RECOMBIVAX HB .....	153
mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50		REGRANEX.....	111
mcg/ml, 500 mcg/ml .....	100	REPATHA .....	106, 107
ondansetron .....	152	REPATHA PUSHTRONEX SYSTEM .	106,
ondansetron hcl oral .....	152	107	
OPSUMIT .....	101	REPATHA SURECLICK.....	106, 107
ORILISSA.....	102	REVLIMID.....	112
ORKAMBI.....	103	RUBRACA .....	113
orphenadrine citrate er .....	60	RYDAPT.....	114
OSPHERA .....	104	<b>S</b>	
oxandrolone oral .....	105	SAMSCA .....	115
<b>P</b>		SANDIMMUNE ORAL SOLUTION ....	153
PEGASYS PROCLICK SUBCUTANEOUS		SENSIPAR.....	153
SOLUTION 180 MCG/0.5ML .....	108	sildenafil citrate oral tablet 20 mg .....	116
PEGASYS SUBCUTANEOUS SOLUTION		sirolimus oral .....	153
.....	108	SOMATULINE DEPOT.....	117
perphenazine-amitriptyline .....	53	SOMAVERT.....	118
phenobarbital oral elixir.....	54	SPRYCEL.....	119
phenobarbital oral tablet .....	54	STIVARGA .....	120
PLEGRIDY.....	90	SUTENT .....	121
PLEGRIDY STARTER PACK .....	90		

# CARE N' CARE HEALTH PLAN

## 2019 Prior Authorization Criteria

SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG, 600 MCG .....	122	trimipramine maleate oral .....	49
SYMDEKO.....	123	TROPHAMINE INTRAVENOUS SOLUTION 10 % .....	153
SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	124	TWINRIX .....	153
SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	124	TYMLOS .....	136
<b>T</b>		<b>U</b>	
tacrolimus oral .....	153	UPTRAVI .....	137
TAFINLAR.....	125	<b>V</b>	
TAGRISSE.....	126	VENCLEXTA.....	138
TAKHZYRO.....	127	VENCLEXTA STARTING PACK .....	138
TALZENNA .....	128	VERZENIO.....	139
TASIGNA .....	129	VIZIMPRO .....	140
TECFIDERA.....	130	VOSEVI.....	44
TENIVAC .....	153	VYVANSE .....	6
testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%) .....	131	<b>X</b>	
testosterone transdermal solution.....	131	XALKORI.....	141
tetanus-diphtheria toxoids td.....	153	XATMEP .....	153
tetrabenazine .....	132	XELJANZ.....	142
THALOMID .....	133	XELJANZ XR .....	142
thioridazine hcl oral .....	53	XGEVA.....	143
TIBSOVO .....	134	XOLAIR .....	144
tigecycline .....	153	XTANDI .....	145
tobramycin inhalation .....	153	XURIDEN.....	146
TPN ELECTROLYTES INTRAVENOUS SOLUTION.....	153	XYREM .....	147
TRACLEER.....	135	<b>Y</b>	
TRAVASOL .....	153	YONSA.....	148
TRELSTAR MIXJECT .....	153	<b>Z</b>	
TREXALL .....	153	zaleplon .....	59
trihexyphenidyl hcl .....	52	ZARXIO .....	94
trimethobenzamide hcl oral.....	50	ZEJULA.....	149
		zolpidem tartrate er .....	59
		zolpidem tartrate oral .....	59
		ZORTRESS.....	153
		ZTLIDO .....	81
		ZYKADIA .....	150
		ZYTIGA ORAL TABLET 500 MG.....	151